Literature DB >> 6416294

Human C1 inhibitor: improved isolation and preliminary structural characterization.

R A Harrison.   

Abstract

An improved procedure for the isolation of the C1 inhibitor (C1-INH) component of human complement is reported. Following preliminary steps to remove plasminogen, fibrinogen, and aggregated material, three conventional chromatographic steps are used to isolate C1-INH in high (70%) overall yield. An extinction coefficient (E 1%, 1 cm 280nm) of 3.60 has been determined. The isolated protein exhibits a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with a mobility corresponding to an apparent molecular weight (Mr) of 105 000. After removal of carbohydrate, the protein shows an increased mobility, corresponding to an apparent Mr of 78 000. A total carbohydrate content of 33% has been calculated, and from this and the size of the deglycosylated polypeptide, a true molecular weight of 116 000 was estimated. Further analysis of the carbohydrate has indicated a galactose:mannose ratio of 2:1 and approximately equimolar amounts of N-acetylglucosamine and N-acetylgalactosamine. This composition is unusual for a plasma protein and suggests that much of the carbohydrate is contained in linkages other than the typical N-glycosidic structures. Values found for the amino acid composition are compared with those reported previously. The amino-terminal sequence (40 residues) of C1-INH is also reported. Asparagine lies at the amino terminus. Neither high-performance liquid chromatography of the released phenylthiohydantoin derivative nor back-hydrolysis of the thiazolinone permitted identification of the residue contained at position 3. The sequence around this position is compatible, however, with an N-glycosidic linkage to residue 3.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6416294     DOI: 10.1021/bi00290a019

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  24 in total

1.  Characterization of C1 inhibitor binding to neutrophils.

Authors:  N S Chang; R J Boackle; R W Leu
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

2.  Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.

Authors:  M H Prandini; A Reboul; M G Colomb
Journal:  Biochem J       Date:  1986-07-01       Impact factor: 3.857

3.  Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.

Authors:  R B Parad; J Kramer; R C Strunk; F S Rosen; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

5.  Complement-subcomponent-C1-inhibitor synthesis by human monocytes.

Authors:  A C Yeung Laiwah; L Jones; A O Hamilton; K Whaley
Journal:  Biochem J       Date:  1985-02-15       Impact factor: 3.857

Review 6.  Aspects of C1-inhibitor biochemistry and pathophysiology.

Authors:  T K Nilsson
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

Review 7.  Deglycosylation of glycoproteins with trifluoromethanesulphonic acid: elucidation of molecular structure and function.

Authors:  Albert S B Edge
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

8.  Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases.

Authors:  P Woo; P J Lachmann; R A Harrison; N Amos; C Cooper; F S Rosen
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

9.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

10.  Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation.

Authors:  K S Aulak; P A Pemberton; F S Rosen; R W Carrell; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.